Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Alcon Research |
---|---|
Information provided by: | Alcon Research |
ClinicalTrials.gov Identifier: | NCT00051155 |
To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.
Condition | Intervention | Phase |
---|---|---|
Glaucoma, Open-Angle Ocular Hypertension |
Drug: Travoprost (0.004%) Drug: Latanoprost (0.005%)/Timolol (0.5%) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 6-Week Safety and Efficacy Study of TRAVATAN Compared to XALCOM in Subjects With Open-Angle Glaucoma or Ocular Hypertension. |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.
Study ID Numbers: | C-01-74 |
Study First Received: | January 3, 2003 |
Last Updated: | August 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00051155 |
Health Authority: | United States: Food and Drug Administration |
Glaucoma POAG OAG OHT |
Glaucoma Eye Diseases Glaucoma, Open-Angle Vascular Diseases Timolol |
Latanoprost Travoprost Hypertension Ocular Hypertension |
Therapeutic Uses Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |